Ascites Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA and Companies by DelveInsight | YZY Biopharma, Healthgen Biotech, Grifols Therapeutics, Versantis

(Albany, United States) As per DelveInsight's assessment, globally, Ascites pipeline constitutes 10+ key companies continuously working towards developing 10+ Ascites treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Ascites Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ascites Market.
The Ascites Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/report-store/ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Ascites Pipeline Report:
• Ascites companies across the globe are diligently working toward developing novel Ascites treatment therapies with a considerable amount of success over the years.
• Ascites companies working in the treatment market are Wuhan YZY Biopharma Co., Ltd., Healthgen Biotechnology Corp., Grifols Therapeutics LLC, Versantis AG, Yale University, Noorik Biopharmaceuticals AG, and others, are developing therapies for the Ascites treatment
• Emerging Ascites therapies in the different phases of clinical trials are- M701, OrsHSA, Albutein 20% Injectable Solution, VS-01 on top of SOC, Empagliflozin 10 MG, Ambrisentan, and others are expected to have a significant impact on the Ascites market in the coming years.
• In December 2023, The US Food and Drug Administration (FDA) has awarded orphan drug designation to Ocelot Bio's lead candidate, OCE-205, for the treatment of ascites, excluding cancer-associated cases. This status is granted by the FDA for therapies aimed at rare diseases or conditions affecting fewer than 200,000 people in the US.
• In November 2023, BioVie Inc. (NASDAQ: BIVI), a clinical-stage company focused on developing innovative drug therapies for advanced liver disease and neurological disorders, has announced positive clinical safety results from its Phase 2b open-label study. The study evaluated the efficacy and safety of BIV201, a continuous infusion of terlipressin, alongside standard of care (SOC) in patients with refractory ascites due to cirrhosis.

Ascites Overview
Ascites is the abnormal accumulation of fluid in the peritoneal cavity, often associated with liver diseases such as cirrhosis. It can also result from malignancies, heart failure, kidney disease, or infections like tuberculosis. Ascites is a common complication of portal hypertension, where increased pressure in the portal vein leads to fluid leakage into the abdominal cavity.
Symptoms of ascites vary depending on the severity. Mild cases may be asymptomatic, while more severe cases can cause abdominal distension, weight gain, discomfort, shortness of breath, and a feeling of fullness. Ascites can lead to complications like spontaneous bacterial peritonitis (SBP) or hepatorenal syndrome, particularly in cirrhotic patients.
Diagnosis involves physical examination, imaging studies such as ultrasound, and analysis of ascitic fluid obtained via paracentesis. This fluid analysis helps determine the cause of ascites by measuring albumin levels, white cell count, and testing for infections or malignancies.
Management depends on the underlying cause. In cirrhosis-related ascites, treatment includes sodium restriction, diuretics, and therapeutic paracentesis. Advanced cases may require a transjugular intrahepatic portosystemic shunt (TIPS) or liver transplantation.
Effective management of ascites aims to control symptoms, prevent complications, and address the underlying condition to improve patient outcomes.

Get a Free Sample PDF Report to know more about Ascites Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Ascites Drugs Under Different Phases of Clinical Development Include:
• M701: Wuhan YZY Biopharma Co., Ltd.
• OrsHSA: Healthgen Biotechnology Corp.
• Albutein 20% Injectable Solution: Grifols Therapeutics LLC
• VS-01 on top of SOC: Versantis AG
• Empagliflozin 10 MG: Yale University
• Ambrisentan: Noorik Biopharmaceuticals AG

Ascites Route of Administration
Ascites pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Ascites Molecule Type
Ascites Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Ascites Pipeline Therapeutics Assessment
• Ascites Assessment by Product Type
• Ascites By Stage and Product Type
• Ascites Assessment by Route of Administration
• Ascites By Stage and Route of Administration
• Ascites Assessment by Molecule Type
• Ascites by Stage and Molecule Type

DelveInsight's Ascites Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Ascites product details are provided in the report. Download the Ascites pipeline report to learn more about the emerging Ascites therapies - https://www.delveinsight.com/report-store/ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Ascites Therapeutics Market include:
Key companies developing therapies for Ascites are - Lindis Biotech, Wuhan Yzy Biopharma Co., Ltd., Clover Biopharmaceuticals, Binhui Biopharmaceutical, Pharmacyte Biotech Inc., And Others.

Ascites Pipeline Analysis:
The Ascites pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Ascites with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ascites Treatment.
• Ascites key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ascites Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ascites market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Ascites drugs and therapies - https://www.delveinsight.com/sample-request/ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Ascites Pipeline Market Drivers
Increasing Prevalence of Liver Diseases, Advancements in Diagnostic Technologies, Innovative Ascites Treatment Approaches, Growing Research and Development, Rising Awareness and Screening Programs, are some of the important factors that are fueling the Ascites Market.

Ascites Pipeline Market Barriers
However, High Ascites Treatment Costs, Limited Ascites Therapeutic Options, Side Effects and Complications, Regulatory Challenges, Limited Awareness in Low-Income Regions, and other factors are creating obstacles in the Ascites Market growth.

Scope of Ascites Pipeline Drug Insight
• Coverage: Global
• Key Ascites Companies: Wuhan YZY Biopharma Co., Ltd., Healthgen Biotechnology Corp., Grifols Therapeutics LLC, Versantis AG, Yale University, Noorik Biopharmaceuticals AG, and others
• Key Ascites Therapies: M701, OrsHSA, Albutein 20% Injectable Solution, VS-01 on top of SOC, Empagliflozin 10 MG, Ambrisentan, and others
• Ascites Therapeutic Assessment: Ascites current marketed and Ascites emerging therapies
• Ascites Market Dynamics: Ascites market drivers and Ascites market barriers

Request for Sample PDF Report for Ascites Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Ascites Report Introduction
2. Ascites Executive Summary
3. Ascites Overview
4. Ascites- Analytical Perspective In-depth Commercial Assessment
5. Ascites Pipeline Therapeutics
6. Ascites Late Stage Products (Phase II/III)
7. Ascites Mid Stage Products (Phase II)
8. Ascites Early Stage Products (Phase I)
9. Ascites Preclinical Stage Products
10. Ascites Therapeutics Assessment
11. Ascites Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Ascites Key Companies
14. Ascites Key Products
15. Ascites Unmet Needs
16 . Ascites Market Drivers and Barriers
17. Ascites Future Perspectives and Conclusion
18. Ascites Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Facioscapulohumeral Muscular Dystrophy Market: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market
• Familial Amyloid Polyneuropathy Market: https://www.delveinsight.com/report-store/familial-amyloid-polyneuropathy-transthyretin-amyloidosis-corino-de-andrades-disease-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/hyperhidrosis-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Molecular Glue Trials: https://www.delveinsight.com/report-store/molecular-glues-competitive-landscape
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/report-store/necrotizing-enterocolitis-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/report-store/pemphigus-vulgaris-market
• Pharma Licensing Services: https://www.delveinsight.com/consulting/licensing-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Refractory Chronic Cough Market: https://www.delveinsight.com/report-store/chronic-refractory-cough-market
• Acral Lentiginous Melanoma Market: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market
• Acute Lung Injury Market: https://www.delveinsight.com/report-store/acute-lung-injury-market
• Ada-scid Competitive Landscape: https://www.delveinsight.com/report-store/ada-scid-competitive-landscape-and-market-insight
• Adrenoleukodystrophy Market: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
• Adult Myopia Market: https://www.delveinsight.com/infographics/adult-myopia-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Anal Cancer Market: https://www.delveinsight.com/report-store/anal-cancer-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Artificial Lung Devices Market: https://www.delveinsight.com/report-store/artificial-lung-devices-pipeline-insight-and-competitive-landscape
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atrophic Vaginitis Market: https://www.delveinsight.com/report-store/atrophic-vaginitis-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cdk4/6 Inhibitor Market: https://www.delveinsight.com/report-store/cdk4-6-inhibitor-market-forecast

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/rare-diseases
Case study: https://www.delveinsight.com/case-study/breast-cancer-market-dynamics-dashboard

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.